Role of Lipoprotein(a) in Cardiovascular Disease. Current and Future Perspectives**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 52, Issue 2, 2008, Pages 132-134

  Berglund, Lars ^a,b   Anuurad, Erdembileg ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

allele specific apo(a) levels; cardiovascular disease; hormone replacement therapy; Lp(a); risk factors

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; EDITORIAL; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPOPROTEIN(A); RISK FACTORS;

EID: 45849151730     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.04.008     Document Type: Editorial

References (20)

1. Utermann G. The mysteries of lipoprotein(a). Science 246 (1989) 904-910
2. Bostom A.G., Cupples L.A., Jenner J.L., et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 276 (1996) 544-548
3. Jauhiainen M., Koskinen P., Ehnholm C., et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 89 (1991) 59-67
4. Maher V.M., Brown B.G., Marcovina S.M., Hillger L.A., Zhao X.Q., and Albers J.J. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274 (1995) 1771-1774
5. Foody J.M., Milberg J.A., Robinson K., Pearce G.L., Jacobsen D.W., and Sprecher D.L. Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 20 (2000) 493-499
6. von Eckardstein A., Schulte H., Cullen P., and Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 37 (2001) 434-439
7. Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmler H.G., and Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80 (1987) 458-465
8. Marcovina S.M., Albers J.J., Jacobs Jr. D.R., et al. Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans. The CARDIA study. Arterioscler Thromb 13 (1993) 1037-1045
9. Danik J.S., Rifai N., Buring J.E., and Ridker P.M. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 52 (2008) 124-131
10. Linden T., Taddei-Peters W., Wilhelmsen L., et al. Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis 137 (1998) 175-186
11. Ruiz J., Thillet J., Huby T., et al. Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia 37 (1994) 585-591
12. Kronenberg F., Kronenberg M.F., Kiechl S., et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100 (1999) 1154-1160
13. Wu H.D., Berglund L., Dimayuga C., et al. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J Am Coll Cardiol 43 (2004) 1828-1833
14. Paultre F., Pearson T.A., Weil H.F., et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 20 (2000) 2619-2624
15. Tuck C.H., Holleran S., and Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arterioscler Thromb Vasc Biol 17 (1997) 1822-1829
16. Marcovina S.M., Koschinsky M.L., Albers J.J., and Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 49 (2003) 1785-1796
17. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
18. Suk Danik J., Rifai N., Buring J.E., and Ridker P.M. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 296 (2006) 1363-1370
19. Cantin B., Despres J.P., Lamarche B., et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol 89 (2002) 662-666
20. Shlipak M.G., Simon J.A., Vittinghoff E., et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 283 (2000) 1845-1852